To this day, although all trials investigating type I interferon IFN-α-based immunotherapies in glioma have not been yielding beneficial results, IFN-α has been reported to resensitize TMZ-resistant glioma cells to TMZ [34–37]. The gene discussed is IFNA1; the disease is central nervous system cancer.